Abstract 441P
Background
To evaluate the effectiveness of radiation therapy (RT) in patients with somatotropic pituitary adenomas, depending on the age of patients and the activity of pituitary adenomas.
Methods
The subject of the study were 50 patients (women-36, men-14) with acromegaly who received gammatherapy in a total dose of 45-60Gr of 20-25fractions every other day. The duration of the disease was 15years on average. In general, the age of patients ranged from 26 to 77years, on average-44.7±6.8years. By age, the patients were divided into 3 groups: the I age group-29-44years-23patients (46%), the IIgroup-45-59year-16patients (32%), the IIIgroup-60-79years, 11patients (22%). All patients underwent hormonal (GH, IGF-1) studies.
Results
The levels of hormones of GH and IGF-1 remained high in the I group in 22% of patients, and in group III in 9%. Remissions reached 64% in the III age group. The highest level of GH content occurred in the age range from45 to59years and was 77.5±9.68mMе/l, and from 26 to 44years it was 68.1±6.84mMе/l. After RT, this indicator in both age groups was almost equally suppressed, but not up to the norm. The decrease in the GH level to normal was observed in I age group in 8patients, and in the II age group in 5patients it was 2.65±2.2mMе/l and 2.23±1.4mMе/l, respectively. In group III, in 11 patients before RT, the mean level of GH was 46.5±8.2mMе/l. After RT, the level of GH decreased in this way: not suppressed only in one patient and was 22.1±0.89mMе/l, in 3patients the level of GH was suppressed, but not up to the norm and amounted to6.7±0.7mMe/l, only 7patients were suppressed and amounted to 2.46±2.2mMe/l.
Conclusions
In all age periods, even in the period of the most activity pituitary adenoma-at the age of 26-44 years, RT is a rather effective method of treatment and gives positive results in most cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session